The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
ApexOnco Front Page
Recent articles
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
ESO-T01 delivers its first four multiple myeloma case reports.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
PD-(L)1 x VEGF bispecifics prove a big draw.
